✦ LIBER ✦

The role of D2and D3dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew)

✍ Scribed by N. A. Darmani; W. Zhao; B. Ahmad

Book ID: 106208196
Publisher: Springer
Year: 1999
Tongue: English
Weight: 259 KB
Volume: 106
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s007020050222

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Delta-9-tetrahydrocannabinol differentia

Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva)

✍ Nissar A. Darmani; Jennifer L. Crim 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 365 KB

Pranlukast prevents cysteinyl leukotrien

Pranlukast prevents cysteinyl leukotriene-induced emesis in the least shrew (Cryptotis parva)

✍ Seetha Chebolu; Yaozhi Wang; Andrew P. Ray; Nissar A. Darmani 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 705 KB

Receptor-selective agonists induce emesi

Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva)

✍ Andrew P. Ray; Seetha Chebolu; Nissar A. Darmani 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 858 KB

Cryptotis parva from Coahuila, Mexico an

Cryptotis parva from Coahuila, Mexico and Comments on the Taxonomy of Least Shrews in Texas

✍ Gerald G. Raun 📂 Article 📅 1965 🏛 Southwestern Association of Naturalists 🌐 English ⚖ 527 KB

Role of dopamine D1 and D2 receptors in

Role of dopamine D1 and D2 receptors in mediating the d-amphetamine discriminative cue

✍ Lesley J. Furmidge; Madlen Exner; David Clark 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 1019 KB

Antiparkinsonian effects of the novel D3

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept